Your browser doesn't support javascript.
loading
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Rosenthal, Seth A; Hunt, Daniel; Sartor, A Oliver; Pienta, Kenneth J; Gomella, Leonard; Grignon, David; Rajan, Raghu; Kerlin, Kevin J; Jones, Christopher U; Dobelbower, Michael; Shipley, William U; Zeitzer, Kenneth; Hamstra, Daniel A; Donavanik, Viroon; Rotman, Marvin; Hartford, Alan C; Michalski, Jeffrey; Seider, Michael; Kim, Harold; Kuban, Deborah A; Moughan, Jennifer; Sandler, Howard.
Affiliation
  • Rosenthal SA; Radiation Oncology, Sutter Cancer Centers, Roseville, California. Electronic address: rosents@sutterhealth.org.
  • Hunt D; NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
  • Sartor AO; Tulane University Medical Center, New Orleans, Louisiana.
  • Pienta KJ; Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Gomella L; Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
  • Grignon D; Indiana University, Bloomington, Indiana.
  • Rajan R; McGill University, Montreal, Quebec, Canada.
  • Kerlin KJ; Community Clinical Oncology Program, Southeast Cancer Control Consortium, Inc, Winston-Salem, North Carolina.
  • Jones CU; Radiation Oncology, Sutter Cancer Centers, Roseville, California; Radiological Associates of Sacramento, Sacramento, California.
  • Dobelbower M; University of Alabama at Birmingham Medical Center, Birmingham, Alabama.
  • Shipley WU; Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
  • Zeitzer K; Albert Einstein Medical Center, Bronx, New York.
  • Hamstra DA; University of Michigan Medical Center, Ann Arbor, Michigan.
  • Donavanik V; Christiana Care Health Services, Inc, Wilmington, Delaware.
  • Rotman M; State University of New York Health Science Center-Brooklyn, Brooklyn, New York.
  • Hartford AC; Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire.
  • Michalski J; Washington University, St. Louis, Missouri.
  • Seider M; Akron City Hospital, Akron, Ohio.
  • Kim H; Wayne State University, Detroit, Michigan.
  • Kuban DA; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Moughan J; NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.
  • Sandler H; Cedars-Sinai Medical Center, Los Angeles, California.
Int J Radiat Oncol Biol Phys ; 93(2): 294-302, 2015 Oct 01.
Article in En | MEDLINE | ID: mdl-26209502
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents, Hormonal / Androgen Antagonists Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2015 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Antineoplastic Agents, Hormonal / Androgen Antagonists Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Int J Radiat Oncol Biol Phys Year: 2015 Document type: Article Country of publication: United States